Robert D. Delp is assuming the position of President, Americas and joining the executive leadership team of Zimmer Biomet Holdings, Inc. on January 23, 2017. This continues to point to a successful merger between Zimmer and Biomet.
Delp is New President, Americas for Zimmer Biomet
1 min read Premium comments
Delp was previously Zimmer Biomet’s Vice President of U.S. Sales, leading sales for the knee, hip, bone cement, biologics, extremities, sports medicine, foot and ankle, surgical and trauma categories.
According to a company announcement on January 17, 2017, Stuart Kleopfer, following a career at Zimmer Biomet and pre-merger Biomet, decided to retire from his position as President, Americas. Kleopfer will “continue with the company for a period of time and work closely with Delp to fully transition responsibilities.” Kleopfer became president of Biomet U.S. in 2011 and has been with the company since 1988.
“I would like to thank Stuart for his significant contributions to the company and congratulate Rob on his new leadership appointment. Rob is a strategic and customer-focused executive, and he is the right leader to continue to grow Zimmer Biomet’s Americas region in the future, ” said Zimmer Biomet President and Chief Executive Officer David Dvorak.
Prior to the combination of Zimmer and Biomet, Delp was Biomet’s Vice President of Sales for several businesses, including sports medicine, extremities, trauma and biologics. He has 20 years of sales leadership experience.
Delp was educated at Grace College and Seminary in Winona Lake, Indiana.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.